{"schema_version":"secwatch.filing_event.v1","accession":"0001801170-26-000148","form_type":"8-K","ticker":"CLOV","cik":"0001801170","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","filed_at":"2026-06-12T20:05:45+00:00","discovered_at":"2026-06-12T20:08:00.291702+00:00","generated_at":"2026-06-12T20:16:33.424015+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Clover Health shareholders elect directors, approve say-on-pay, ratify E&Y at 2026 meeting","bullets":["Demetrios L. Kouzoukas, Andrew Toy, Thomas L. Tran elected as Class II directors until 2029.","Non-binding advisory vote on 2025 NEO compensation approved with ~1.00B votes for, ~9.8M against.","Ratification of Ernst & Young as independent auditor for FY2026 approved with ~1.19B votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001801170-26-000148","json":"https://secwatch.observer/filing/0001801170-26-000148.json","markdown":"https://secwatch.observer/filing/0001801170-26-000148.md","text":"https://secwatch.observer/filing/0001801170-26-000148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000148/0001801170-26-000148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000148/clov-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:16:33.424015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cf036ba9e9ae4d666bc868bcd8140908593227c","claim":"CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025 at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 2: Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025. The stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2025. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 1,003,065,402 9,811,825 1,663,812 177,790,033","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000148/0001801170-26-000148-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"3b56fae735f2adb78836c1e60e97e2f01bb34742","claim":"CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Election of Three Class II Directors at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 1: Election of Three Class II Directors. Demetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran were each elected to the Company’s Board of Directors as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the election were as follows: FOR WITHHELD BROKER NON-VOTE Demetrios L. Kouzoukas 1,003,131,251 11,409,888 177,790,033 Andrew Toy 1,011,117,814 3,423,325 177,790,033 Thomas L. Tran 996,918,879 17,622,260 177,790,033","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000148/0001801170-26-000148-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"5add3b176426c3f0df606add59d9756453036fa4","claim":"CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: FOR AGAINST ABSTAIN 1,188,467,663 2,471,606 1,391,903","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117026000148/0001801170-26-000148-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}